BioCentury
ARTICLE | Finance

Ebb & Flow

March 19, 2007 7:00 AM UTC

Two new companies, Tragara Pharmaceuticals and Epiphany Biosciences, landed large series A rounds last week. Each was formed around recently in-licensed compounds and hopes to get to a major value inflection point, Phase IIb results, with this initial funding.

Deals like these have consistently pushed up the size of A rounds over the last several years (see "A Trend"). ...